ResultsIQ

ResultsIQ › Latest results › Camlin Fine Sciences Limited

Camlin Fine Sciences Limited Q4 FY25 results deck summary

NSE: CAMLINFINE · BSE: 532834

Results deck of 23 May 2025, summarised by AI from the filing.

Camlin Fine Sciences FY25 revenue rose 15% to ₹16,665 mn and adjusted EBITDA 13% to ₹2,081 mn, with net debt down to ₹4,918 mn.

Key takeaways

  1. Q4 FY25 revenue Revenue from operations was ₹4,374.6 mn (Q4 FY24: ₹3,766.5 mn, +16.1%).
  2. FY25 adjusted EBITDA Adjusted EBITDA for FY25 improved by 13% to ₹2,081 mn on YoY basis.
  3. Net debt reduction Net Debt stood at ₹4,918 million as of March 2025, down from ₹5,641 million in March 2024.
  4. Blends growth Blends revenue grew 18% to ₹8,784 mn in FY25, with healthy growth expected to continue in North America and Domestic market.
  5. Discontinued operations PBT from discontinued operations was negative ₹2,075.2 mn in FY25.

Original filing on BSE

Camlin Fine Sciences Limited Q1 FY27 results

As filed: Revenue ₹520 cr (+23% year on year), EBITDA ₹9.3 cr (−51% year on year), PAT −₹33.6 cr, EBITDA margin 1.8% (−270 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹425 cr (−3% year on year), EBITDA ₹21.2 cr (−64% year on year), PAT ₹86.3 cr (−96% year on year), EBITDA margin 5.0% (−852 bps). Score 27 of 100, Below trend. Revenue and profit before exceptional items growth were well below the company's own trend; EBITDA growth was below it. EBITDA margin fell 852 bps year on year. Revenue fell 7% from last quarter. Share price after the results: +12.2% in 30 days (Nifty 500: +0.9%).
  • Q3 FY26: Revenue ₹457 cr (+6% year on year), EBITDA ₹22.0 cr (−55% year on year), PAT −₹37.1 cr (−300% year on year), EBITDA margin 4.8% (−650 bps). Score 20 of 100, Below trend. Revenue growth was in line with the company's own trend; EBITDA growth was below it; profit before exceptional items growth was well below it. EBITDA margin fell 650 bps year on year. Share price after the results: −18.1% in 28 days (Nifty 500: −8.2%).
  • Q2 FY26: Revenue ₹460 cr (+9% year on year), EBITDA ₹33.0 cr (−23% year on year), PAT −₹15.0 cr, EBITDA margin 7.2% (−299 bps). Score 45 of 100, In line with trend. Revenue growth was above the company's own trend; EBITDA growth was in line with it. EBITDA margin fell 299 bps year on year. Share price after the results: −23.6% in 30 days (Nifty 500: −0.8%).
  • Q1 FY26: Revenue ₹424 cr (+7% year on year), EBITDA ₹19.0 cr (+6% year on year), PAT −₹11.0 cr, EBITDA margin 4.5% (−6 bps). Score 45 of 100, In line with trend. Revenue growth was above the company's own trend; EBITDA growth was in line with it. EBITDA margin was flat year on year. Share price after the results: −14.4% in 28 days (Nifty 500: +1.7%).
  • Q4 FY25: Revenue ₹437 cr (+9% year on year), EBITDA ₹59.0 cr, PAT ₹0.0 cr, EBITDA margin 13.5% (+1,000 bps). Score 70 of 100, Above trend. Revenue growth was well above the company's own trend. EBITDA margin rose 1000 bps year on year. Other income 34% of PBT. Share price after the results: +60.5% in 28 days (Nifty 500: +1.1%).
  • Q3 FY25: Revenue ₹433 cr (+12% year on year), EBITDA ₹49.0 cr (+113% year on year), PAT −₹7.0 cr, EBITDA margin 11.3% (+536 bps). Score 45 of 100, In line with trend. Revenue and EBITDA growth were well above the company's own trend. EBITDA margin rose 536 bps year on year. Other income 50% of PBT. Tax rate 350%.
  • Q2 FY25: Revenue ₹423 cr (+4% year on year), EBITDA ₹43.0 cr (+72% year on year), PAT −₹116 cr, EBITDA margin 10.2% (+401 bps). Score 69 of 100, Above trend. EBITDA margin rose 401 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Camlin Fine Sciences Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.